Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Multiple Myeloma 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Prostatic Neoplasms 1Paraproteinemias 1Neoplasms, Plasma Cell 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia 1Colorectal Neoplasms 1Brain Neoplasms 1

Interventions

pembrolizumab 90Carboplatin 78Specimen Handling 76Magnetic Resonance Spectroscopy 63Pemetrexed 60Cisplatin 48durvalumab 44Paclitaxel 38Nivolumab 34atezolizumab 32Radiosurgery 30osimertinib 29Radiotherapy 29Blood Specimen Collection 26Biopsy 26Gemcitabine 24Docetaxel 24Immunoglobulin G 23Standard of Care 22Disulfides 22Drug Therapy 21Etoposide 20Taxes 18Practice Guidelines as Topic 18Radiation 17Educational Status 16130-nm albumin-bound paclitaxel 15X-Rays 14Surveys and Questionnaires 14Bevacizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Chromatin Immunoprecipitation Sequencing × 1 year × Clear all
NCT07291414 2026-01-21

A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients

University of Michigan Rogel Cancer Center

Phase NA Recruiting
80 enrolled
BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡